Home › Targets › ITGAV
Radioligand therapy target profile

ITGAV: IHC Expression in Cancer and Radioligand Target Profile

integrin subunit alpha V · Ensembl ENSG00000138448 · Data updated 2026-11-01

ITGAV, integrin subunit alpha V, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, ITGAV staining is highest in head and neck cancer (100% of samples positive), thyroid cancer (100% of samples positive) and bladder cancer (100% of samples positive). Clinical status: FDA-approved drug (any modality).

Is ITGAV the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.

Analyze ITGAV free
LocalizationCell-Surface
Top cancer (IHC)Head and Neck Cancer
InternalizationNot assessed
Clinical stageFDA-approved drug (any modality)
Active trialsSee ClinicalTrials.gov
Cancer association (Open Targets)0.44

Is ITGAV a good radioligand therapy target?

Scored against the six criteria that decide whether a protein can become a radioligand therapy:

ITGAV IHC staining by cancer type

Protein expression of ITGAV across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.

Cancer typeIHC scoreLevel% positive
Head and Neck Cancer0.83High100%
Thyroid Cancer0.83High100%
Bladder Cancer0.82High100%
Glioma0.72High100%
Endometrial Cancer0.70High100%
Melanoma0.67High100%
Kidney Cancer0.61High92%
Ovarian Cancer0.58High100%
Pancreatic Cancer0.56High89%
Cervical Cancer0.53High100%
Breast Cancer0.50Medium83%
Skin Cancer0.48Medium64%
Lung Cancer0.47Medium75%
Prostate Cancer0.47Medium100%
Gastric Cancer0.39Medium67%
Colorectal Cancer0.36Medium100%
Liver Cancer0.36Medium67%
Neuroendocrine Tumors0.33Medium50%
Lymphoma0.14Low33%

Not detected by IHC in: testicular cancer.

Is ITGAV internalized?

Nuclens has not yet extracted internalization evidence for ITGAV. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a free analysis to pull the latest literature.

ITGAV clinical trials

FDA-approved drug (any modality). Nuclens hasn't indexed trials for ITGAV yet. Search ClinicalTrials.gov for ITGAV trials.

ITGAV normal tissue expression

Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See ITGAV in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.

ITGAV gene essentiality (DepMap)

CRISPR knockout effect across 1258 cancer cell lines: -0.50 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.

Related head and neck cancer radioligand targets

EGFR · c-MET (MET) · HER3 (ERBB3) · SSTR2 · B7-H3 (CD276) · STEAP2 · HER2 (ERBB2) · Mesothelin (MSLN)

See all radioligand therapy targets in head and neck cancer.

See how ITGAV ranks against 15,000 targets for your indication.

Analyze ITGAV free

Data sources

Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.

Is ITGAV the right target for your program? · 5 free analyses, no card Analyze ITGAV free